EHR alerts aim to close gap in heart valve care
NCT ID NCT06099665
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether automated alerts in electronic health records help doctors identify and treat patients with severe aortic stenosis or mitral regurgitation. Over 2,100 patients were included, and some doctors received alerts while others did not. The goal was to see if alerts increase the number of patients who get a heart valve procedure or see a heart specialist, and whether this reduces racial, ethnic, and geographic gaps in care.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Automated alert via electronic health record (EHR)
- What this could lead to
- If successful, this could show that simple computer alerts help doctors catch and treat severe heart valve problems earlier, especially in groups that often miss out on care.
- What could go wrong
- This is a completed study, so results are known but not yet widely applied. Alerts may not change doctor behavior enough, or benefits may not hold across all hospitals or patient groups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
2,118 people
The number who actually took part.
- Started
-
Aug 2024
- Finished
-
Dec 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
At least one of the following three options for aortic stenosis and/or the single option for mitral regurgitation are determined from echocardiogram findings: 1. AVA or DI (Patients with either Aortic valve area (AVA) or Dimensionless Index (DI) measured in their echo as well as at least one hemodynamic measure above the minimum threshold) a. Either: i. Aortic Valve Area ≤ 1.0 cm2 ii. Dimensionless Index ≤ 0.25 b. AND ANY of i. Aortic Mean Gradient ≥ 15 mmHg ii. Aortic Peak Gradient ≥ 30 mmHg iii. Aortic Jet Velocity ≥ 2.75 m/s 2. AVA + OTHER (Patients with AVA and at least 1 other echo measurement in their echo above the threshold) 1. 1.0 cm2 \< Aortic Valve Area ≤ 1.2 cm2 2. AND ANY of: i. Aortic Mean Gradient ≥ 40 mmHg ii. Aortic Peak Gradient ≥ 64 mmHg iii. Aortic Jet Velocity ≥ 4.0 m/s 3. POSSIBLE (Possible Aortic Stenosis but requires human review) a. Aortic Valve Area is NULL OR \>1.2 cm2 b. AND ANY of: i. Aortic Mean Gradient ≥ 40 mmHg ii. Aortic Peak Gradient ≥ 64 mmHg iii. Aortic Jet Velocity ≥ 4.0 m/s OR a. EITHER i. Aortic Valve Area ≤ 1.0 cm2 ii. Dimensionless Index ≤ 0.25 b. AND ALL are: i. Aortic Mean Gradient \< 15 mmHg ii. Aortic Peak Gradient \< 30 mmHg iii. Aortic Peak Velocity \< 2.75 m/s ALERT Study Clinical Investigation Plan Version 2.1 page 12 of 54 Any patient flagged for "POSSIBLE" does not result in automatically alerting the provider, instead a notification is sent to the Tempus research team for manual review in conjunction with the site Principal Investigator (PI) and if requested by Tempus or site PI, a Steering Committee member. If clinical confirmation is received for severe aortic stenosis from the site PI, an alert is sent to the provider. 1. Mitral Regurgitation a. Mention of severe mitral regurgitation or moderate- severe mitral regurgitation Any patient mentioned with only moderate MR or a lesser severity will be excluded. Exclusion Criteria: 1. Age \< 18 years 2. Patient had evidence of a prior transcatheter or surgical repair or replacement of the target valve 3. The echocardiogram was ordered by a cardiologist on the MHT or a cardiac surgeon 4. Patient already has a scheduled clinic visit with a member of the MHT or a recent (since the start of the study at that site ) clinic visit with the MHT, or a scheduled transcatheter or surgical VI in the future.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Aortic valve stenosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Bon Secours Mercy Health - Lima Market
Lima, Ohio, 45801, United States
-
Bon Secours Mercy Health - Richmond Market
Richmond, Virginia, 23223, United States
-
OhioHealth
Columbus, Ohio, 43202, United States
-
Oregon Health and Science University
Portland, Oregon, 97239, United States
-
Saint Luke's Health System
Kansas City, Missouri, 64111, United States
-
Vanderbilt
Nashville, Tennessee, 37235, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Earlier blood thinner may cut clot risk in heart procedures
- Can aggressive blood pressure treatment slow aortic valve disease?
- Why do animal heart valves wear out? immune system under investigation
- One scan to rule them all? new CT aims to replace multiple heart tests
- A simple pressure reading may expose hidden mitral valve leakage after keyhole repair
- Which heart valve design wins for small aortic openings?